


<b>Name of Sponsor:</b> IRCCS OSPEDALE SAN RAFFAELE - Prof. Fabio Ciceri		<b>Statement on discontinuation of the study</b>	 <b>I.R.C.C.S. Ospedale San Raffaele</b> Gruppo San Donato
<b>Investigational Product:</b> Cyclophosphamide Filgrastim Rituximab Etoposide		<b>EudraCT No.:</b> 2007-005506-42	
		<b>Page:</b> 1	
<b>Report Date:</b> 17-SEP-2021	<b>Trial No. / Doc. No.:</b> NHL-HIV+		
<b>Title of Trial:</b>	HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT		
<b>Trial Sites:</b>	NA		
<b>Publications:</b>	NA		
<b>Clinical Phase:</b>	II		
<b>Statement on discontinuation of the study:</b>	<p>Contrary to the initial hypothesis, the number of patients with HIV + lymphomas responding to the inclusion criteria has decreased over time, with a strong delay in enrollment.</p> <p>This has led to the decision to stop the study early.</p> <p>The study ended without enrolling the expected number of patients. Insufficient data for analysis.</p>		